SGMO Sangamo Therapeutics Inc

$SGMO and I are working everyday, along with all other equity committee members, to create value and do best by equity and for equity. Info will be released publicly at the appropriate time and hopefully sooner rather than later. This has been a tremendous obligation on our time for which we are being paid nothing. Best regards all.

$SGMO I just posted my updated Equity Waterfall on X since we had the Claims Register filing as of Oct 5, and the August MOR......

$SGMO Well folks, being stuck in the Expert Market absolutely sucks, but it doesn't change my equity waterfall analysis or my outlook on potential shareholder recovery. Personally, I hate being limited to selling only in such an unbalanced, illiquid market. The flexibility to buy additional shares on positive news or sell/trim a position when necessary has been severely compromised. Unfortunately, this is one of the risks of investing in a company navigating Chapter 11 bankruptcy. That said, the underlying assets, potential milestone payments, and remaining liabilities haven't suddenly changed because of this trading restriction. For me, the focus now shifts back to what really matters: the upcoming Chapter 11 reorganization plan, remaining asset sales, and ultimately what value can be preserved for existing shareholders. Frustrating? Absolutely. But my investment thesis remains unchanged.

$SGMO As we approach the asset sale/auction for the remaining assets, I believe we're simply in a bit of a lull right now. Between trading on the Expert Market and the lack of recent filings, there really hasn't been much to discuss. However, once the auction is completed, we should have a much clearer picture of the equity waterfall and what shareholders can realistically expect. In my opinion, there's no reason this bankruptcy should drag on beyond the December 23 deadline. In fact, I'm hoping they file well before that date. Either way this all comes to head in the next 6-8 weeks. As far as when you might receive any payment, that is another story. Still unknown if there will be some sort of Sangamo 2.0, which could lead to a payment and equity in the new co. Either way I think you're looking at several months possibly longer before you receive anything, just my opinion........

$SGMO Since the current shareholder committee consists of retail investors—people like you and me—they will use their decision-making power to secure solutions that generate maximum value for shareholders. They are not going to chase "pipe dreams" that would put their own protected capital at risk. I do not know with absolute certainty whether this specific scenario is being finalized behind closed doors—but I suspect we will find out soon enough.

$SGMO I see only one reason for this new information. The EC is looking to acquire or reverse merge another profitable company to maximize NOL value. Clearly the target is unrelated business, so hopefully the tax lawyers have figured out that wrinkle. Yes, there is always the possibility that the newco might retain st503 and try to develop it, but i firmly believe that would be a fool’s errand at this stage. Therefore my assumption is they will sell st503, acquire the target, refloat SGMO, and pay a special dividend to existing shareholders equivalent of at least the remaining cash plus discounted milestone value. I trust and pray the EC is creating an immediate value proposition equivalent to full distribution of asset sale cash/milestones. Whatever longer term potential value is available should be a bonus and NOT predicated on tying up or utilizing any existing asset sale cash.

$SGMO it must be chiselled in our minds that the current share price does not reflect at all the value of the estate in the Ch11 case. I had some margin calls Friday when the price dropped to $.06 so was forced to convert some £ to $... but I am still here with my 79k shares at $.21 I am good at waiting, I am very resilient, bt I'll see the end of this one! For many years I've traded Sangamo, made money lost money, it's the nature of this game.

$SGMO So, here is my summary based on the latest dockets. I anticipate that the Chapter 11 proceedings will result in a payout of approximately $0.30 to $0.35 per share. Furthermore, existing shareholders will receive new shares in "Sangamo 2.0"—this is because the plan sponsor cannot wipe out the original shareholders, as doing so would forfeit the value of the tax assets (tax attributes). In addition, existing shareholders will receive CVRs (Contingent Value Rights) equivalent to $0.24 per share. We are seeing the same playbook here that was used in the Hertz case.

$SGMO Just posted on Sangamo website: ST-520 is finally going to auction!!! In my mind, that pretty much confirms a sale with proceeds to be distributed, not a re-float. Expected to be completed in 4Q

$SGMO In fact, the intrinsic value has likely increased, given the pending auctions and the potential monetization of the public shell company. I also believe that the hemophilia program will find a buyer. Anyone selling now is beyond help. The "Expert Market" enforces the patience required until the payout occurs… In my view, Grekko’s "waterfall" calculations are actually on the conservative side…

$SGMO can't help but wonder if our fellow shareholders representing us on the committee have been sucked into the morass that is SGMO - would love to see some sort of timeline commitment - that we used to have - in terms of court dates - now - no idea when this is going to be put to bed and/or if there is SGMO - part 2 - which i wholeheartedly vote NO on - btw - please lets get this done - please put out next steps and a timeline - this is way overdue to be done - it's mid - october - this was supposed to be done early to mid - September

$SGMO FYI I got a notice in my email Nov. 4 that the ST-503 trial has been suspended...that's all I know...screenshot from the trial site:

$SGMO For those who find the wait too long—or who fear that Sangamo’s remaining IP might be worthless—it is well worth taking a look at XOMA, PDL BioPharma, and Ligand Pharmaceuticals:

$SGMO as if we didn’t know already, I think it’s abundantly clear that mgmt is actively trying to harm shareholders. Hope they get exposed and incur whatever wrath the justice system can impose on them.

$SGMO I calculate a cash position of 110 million by the end of August—roughly 0.26 dollars per share. Base is the MOR Report from August

$SGMO Updated waterfall using the latest filings through D539: Post-DIP cash: ~$120.8M Less remaining claims / fees / reserves: ~-$42.4M Residual cash: ~$78.4M = ~$0.19/share * ST-503 / Remaining Assets: ~$50M * Sangamo France: ~$15M * Fabry milestone PV: ~$42M * NOL / Plan Sponsor / other value: ~$15M * Warrants: ~-$4M Central recovery: ~$196M = ~$0.47-$0.48/share. Importantly, cure costs and a large portion of professional fees have already been paid/funded, so they should not be double-counted. And the upside is still open: Remaining Asset bids are due Nov. 13, auction Nov. 17 if competitive, and Plan Sponsor bids remain open through plan confirmation. $0.47-$0.48 is my current central case — not the ceiling.

$SGMO $SGMO on the "expert market now " ... Quotations in Expert Market securities are restricted from public viewing manipulation trades so far this morning 1 cent to .143 volume 100K only value still at least .25 .50 with Fabry approval date set for omnibus hearing december15

$SGMO Really wish the $80K I put into this was still in $XERS Knew what I was getting into though. When you speculate sometimes you lose. Would be happy to get my $80K back but with XERS killing it, I won't miss it. Did anyone buy some XERS when I was telling you to a couple years ago or whenever it was?

$SGMO I’d love for the old Biogen/Novartis/Genentech milestone numbers to still belong to shareholders — I have a lot at stake here too — but the documents don’t support that. Biogen and Novartis were terminated in 2023, so no future milestones/royalties remain for Sangamo. Genentech is different, but the relevant future economic rights were transferred with the Merope/Lilly transaction. So we should not include those old headline numbers in our recovery estimates. Better to stay realistic: cash, ST-503, Fabry, France, NOLs/Plan Sponsor and any other value actually supported by the filings.

$SGMO per court documents now employed a french consultant to assist with the french operations.# 550